UnknownNot Applicable

Evaluation of Oral EGCG Treatment for L-SIL Associated With HPV Infection

Italy50 participantsStarted 2024-03-01

Plain-language summary

The study aims to evaluate the effectiveness of the synergy of oral Epigallocatechin Gallate as a treatment for Low-grade Cervical Lesions (L-SIL) associated with Human Papilloma Virus (HPV) infection.

Who can participate

Age range18 Years – 65 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Women affected by Low-grade Cervical Lesions (L-SIL) associated with Human Papilloma Virus (HPV) Infection Exclusion Criteria: * Pregnancy * Concomitant pathologies causing immunosuppression * Concurrent Immunomodulatory therapies * Hormone replacement therapy * High-grade Cervical Lesions (H-SIL) or in situ adenocarcinoma * Previous history of L-SIL or higher grade lesions ≥ 24 months

What they're measuring

Persistence

Timeframe: After 6, 12, 18, and 24 months from the recruitment

Trial details

NCT IDNCT06314113

SponsorUniversity of Palermo

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-03-01

Contact for this trial

Antonio Simone Laganà, M.D., Ph.D.

+39 3296279579 antoniosimone.lagana@unipa.it

View on ClinicalTrials.gov More Low-Grade Intraepithelial Neoplasia of Cervix trials